Watton Corey Michael

Director Watton Corey Michael buys 300 ZVRA shares at $7.84; stock down -22.6% from 52-week high.

Watton Corey Michael, a Director at ZEVRA THERAPEUTICS, purchased 300 shares at $7.84 on 2025-03-28, increasing his holdings by 20.0% to 1,800 shares total. The transaction occurs when the stock is trading at $7.49, down -22.6% from its 52-week high of $9.68 and down -10.2% over the past 90 days. Reviewing his same-ticker trade history at ZVRA, he has executed 4 prior buys with mixed timing: his October 2024 purchase yielded +13.7% in 30 days and +7.8% in 90 days, while his three 2023 purchases posted negative 30- and 90-day returns, with only 2 of 4 prior purchases achieving positive 90-day returns. The company itself reported a net income of $-33.2M in the latest full year, negative annual revenue growth of -14.0%, and operates unprofitably. The modest transaction value of $2.4K represents a relatively small absolute commitment relative to the director's existing position, and the timing relative to fundamental deterioration and recent price weakness offers limited clarity on directional conviction at this price level.

Director Watton Corey Michael bought 500 ZVRA shares at $7.92; stock now $8.46, up 8.7% in 30 days. Prior ZVRA buys mostly underwater.

Director Watton Corey Michael purchased 500 shares at $7.92 on 2024-10-11, increasing his holdings from 1,000 to 1,500 shares (+50.0% growth in position size). The stock has performed well since the transaction date, rising 8.7% over 30 days and 32.8% over 90 days, currently trading at $8.46. However, this positive near-term performance contrasts sharply with the insider's prior trading history at ZVRA: his three previous purchases (2023-06-23, 2023-06-09, and 2023-05-30) delivered negative 30-day and 90-day returns in two of three cases, with only 1 of 3 prior buys achieving positive 90-day results. His cross-ticker track record shows similar challenges, with an average 90-day return of -6.8% and a 33.33% win rate. ZVRA fundamentals present a turnaround narrative: the company generated $4.4M in quarterly revenue with strong 162.6% annual growth, but reported a $-19.9M net loss and remains unprofitable. The director's repeated accumulation despite prior underwater outcomes warrants observation of whether this reflects genuine conviction or mechanical buying in a volatile, pre-profitability biotech.